Maarten van der Doelen

Chapter 7

Supplementary table 4A. Univariate analysis of overall survival.

median OS (months)

Hazard ratio

95% CI

N

P

Number of prior therapies

93

0-1

18

22.1

1.00

≥2

27

19.0

1.44

0.81-2.53 0.212

Extent of disease

89

0.999

< 6 metastases

10

26.1

1.00

6-20 metastases

39

20.4

1.06

0.40-2.85 0.906

> 20 metastases

38

20.9

1.05

0.40-2.77 0.922

Superscan

2

20.5

1.14

0.13-.9.86 0.903

ECOG performance status

87

ECOG 0

62

20.8

1.00

ECOG 1-2

25

21.1

1.13

0.59-2.19 0.714

Opioid use

84

No

60

19.0

1.00

Yes

24

22.4

0.61

0.31-1.21 0.156

Baseline ALP level

93

< 115 U/L

44

26.1

1.00

0.046

≥ 115 U/L

49

19.8

1.78

1.01-3.13

PARP or platinum after radium-223

91

No

80

20.5

1.00

Yes

11

30.0

0.524

0.21-1.33 0.173

Mutation in DDR genes

93

DDR-

65

17.0

1.00

DDR+ 0.011 ALP, alkaline phosphatase; CI, confidence interval; DDR, DNA damage repair; ECOG, Eastern Cooperative Oncology Group; OS, overall survival. 28 36.3 0.44 0.23-0.83

194